Table 2.
Comparison of outcome between in patients with AKI stages 1A and 1B, categorized according to level of serum creatinine at admission
| Sl. no | Parameters | AKI 1A (n = 100) | AKI 1B (n = 82) | P value | |
|---|---|---|---|---|---|
| 1 | ACLF (APASL) (%) | 24 (24) | 32 (39.02) | 0.029 | |
| 2 | ACLF (CANONIC) (%) | 24 (24) | 43 (52.4) | <0.001 | |
| 3 | Grade of ACLF (%) | ACLF 0 | 76 (76) | 39 (47.6) | <0.001 |
| ACLF 1 | 19 (19) | 21 (25.6) | |||
| ACLF 2 | 5 (5) | 15 (18.3) | |||
| ACLF 3 | 0 (0) | 7 (8.5) | |||
| 4 | HRS (%) | 6 (6) | 25 (30.5) | <0.001 | |
| 5 | Reversal of AKI (%) | 86 (86) | 53 (64.6) | 0.001 | |
| 6 | Duration of hospital stay (days) (Median [IQR]) | 4 (3–5) | 6 (4–7) | 0.012 | |
| 7 | 28 days survival (%) | 82 (82) | 54 (65.9) | 0.013 | |
| 8 | 90 days survival (%) | 61 (61) | 33 (40.2) | 0.005 | |
ACLF, acute on chronic liver failure; AKI, acute kidney injury; APASL, Asian Pacific Association for the Study of the Liver; CANONIC, Consortium Acute‐on‐Chronic Liver Failure in Cirrhosis; HRS, hepatorenal syndrome; IQR, interquartile range.